Vir Biotechnology president and CEO George Scangos explains why many companies struggle to build a sustainable business model around fighting infectious diseases, particularly when it comes to developing antibiotics. However, he adds, certain therapies for viral diseases are currently more financially viable. Dr. Scangos explores why Vir decided to go “all-in” on infectious diseases, how they built a company around that mission, and how the arrival of COVID-19 impacted the young company’s trajectory.
Related
Luke Sykora,
Stanford University
Starting Up in a Downturn
An Entrepreneurial Thought Leaders mini-guide for aspiring founders facing a troubled economy.
Josh Makower, MD,
Stanford Byers Center for Biodesign
The Biodesign Innovation Process [Entire Talk]
Innovation isn’t random – it’s a process that can be learned, improved, and effectively deployed to solve specific problems.
Josh Makower, MD,
Stanford Byers Center for Biodesign
The Biodesign Innovation Process [Entire Talk]
Innovation isn’t random – it’s a process that can be learned, improved, and effectively deployed to solve specific problems.
John Felts,
Cruz Foam
Engineering Green Materials [Entire Talk]
To scale a technology, engineers need to think beyond the technology itself.
John Felts,
Cruz Foam
Engineering Green Materials [Entire Talk]
To scale a technology, engineers need to think beyond the technology itself.
